Literature DB >> 9506529

rhG-CSF affects genes involved in mitogen signalling and early gene expression in the ovarian cancer cell line HEY.

T Brandstetter1, E Ninci, U Falken, E Wagner, R Hess, T Bauknecht.   

Abstract

The ovarian adenocarcinoma cell line HEY was used as an in vitro model to study the influence of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on epithelial tumours such as ovarian cancer. Serum-starved cells were treated with rhG-CSF in a time- and dose-dependent manner. Cell proliferation, measured as cell division and DNA synthesis, was stimulated about 40% by rhG-CSF. After harvesting, cells were examined for the presence of G-CSF receptor (FACS analysis and RT-PCR), as well as for expression of genes involved in mitogen signalling (ERKs, JNKs) and early gene expression (c-jun). rhG-CSF affected mitogen-activated pathways and was receptor-mediated if the G-CSF receptor was present. After rhG-CSF induction, Janus N-terminal kinases (JNK 1 and 2) were simultaneously increased in the cytosol, up to 30-fold as measured by Western blotting), whereas ERK 1 and 2 accumulated maximally by 2.5-fold 1 hr after rhG-CSF induction. c-Jun was up-regulated strongly by this cytokine at the translational level. Our data suggest that rhG-CSF affects genes involved in mitogen signalling and early gene expression in solid tumours. We also noted the presence of G-CSF receptor on ovarian cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506529     DOI: 10.1002/(sici)1097-0215(19980316)75:6<847::aid-ijc6>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.

Authors:  J Kumar; F W Fraser; C Riley; N Ahmed; D R McCulloch; A C Ward
Journal:  Br J Cancer       Date:  2013-11-12       Impact factor: 7.640

2.  Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.

Authors:  Yuan-Yuan Zhao; Li Yu; Bao-Ling Liu; Xin-Jia He; Bi-Yuan Zhang
Journal:  Mol Med Rep       Date:  2015-09-25       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.